RT Journal Article
SR Electronic
T1 Novel Midkine Inhibitor iMDK Inhibits Tumor Growth and Angiogenesis in Oral Squamous Cell Carcinoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2775
OP 2781
VO 36
IS 6
A1 MASANORI MASUI
A1 TATSUO OKUI
A1 TSUYOSHI SHIMO
A1 KIYOFUMI TAKABATAKE
A1 TAKUYA FUKAZAWA
A1 KENICHI MATSUMOTO
A1 NAITO KURIO
A1 SOICHIRO IBARAGI
A1 YOSHIO NAOMOTO
A1 HITOSHI NAGATSUKA
A1 AKIRA SASAKI
YR 2016
UL http://ar.iiarjournals.org/content/36/6/2775.abstract
AB Midkine is a heparin-binding growth factor highly expressed in various human malignant tumors. However, its role in the growth of oral squamous cell carcinoma is not well understood. In this study, we analyzed the antitumor effect of a novel midkine inhibitor (iMDK) against oral squamous cell carcinoma. Administration of iMDK induced a robust antitumor response and suppressed cluster of differentiation 31 (CD31) expression in oral squamous cell carcinoma HSC-2 cells and SAS cells xenograft models. iMDK inhibited the proliferation of these cells dose-dependently, as well as the expression of midkine and phospho-extracellular signal-regulated kinase in HSC-2 and SAS cells. Moreover, iMDK significantly inhibited vascular endothelial growth factor and induced tube growth of human umbilical vein endothelial cells in a dose-dependent fashion. These findings suggest that midkine is critically involved in oral squamous cell carcinoma and iMDK can be effectively used for the treatment of oral squamous cell carcinoma.